Vanguard Australian Shares Index Etf

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Vanguard MSCI Index International Shares Etf

VGS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

CSL Limited

CSL

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 30,000 full-time employees. The Company’s areas of focus and exploration include rare and serious diseases, influenza vaccines, plasma collection, and therapies for iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment manufactures, markets, and distributes plasma therapies (plasma products and recombinants). CSL Seqirus segment manufactures, markets, and distributes primarily influenza-related products and provides pandemic services to governments. The Company’s CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency, dialysis and nephrology and rare diseases. The Company’s geographical areas of operation include Australia, the United States of America, Germany, the United Kingdom, Switzerland, and China. CSL’s products include HIZENTRA, PRIVIGEN, IDELVION, HAEMATE, KCENTRA, HAEGARDA, ZEMAIRA/RESPREEZA, FLUAD and FLUCELVAX.

iShares S&P 500 Etf

IVV

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.